CALLAN JMB INC.
callanjmb.comCallan JMB Inc (OTC: CJMB) is a vertically integrated cold chain logistics and fulfillment company that provides thermal management logistics solutions to the life sciences industry. Revenue comes from bundled service offerings that combine proprietary reusable packaging, the Sentry advanced monitoring platform, and specialized cold chain logistics, including emergency response deployment. The company serves customers in highly regulated industries, including personalized medicine, cell therapies, stem cells, vaccines, diagnostic materials, organs, and biopharmaceuticals, with noted relationships spanning Fortune 500 firms, the City of Chicago, NATO, the United Nations, and government agencies at multiple levels, per its 10-K filed March 31, 2026. The business operates a leasing model for packaging systems and positions its cryogenic and frozen-temperature solutions as alternatives to dry ice and liquid nitrogen. The filing discloses that the company is capital-intensive, has a holding company ownership structure, and depends on distributions from operating subsidiaries to meet obligations.
Products & Services
Proprietary reusable cryogenic and frozen-temperature packaging systems; Sentry advanced monitoring platform tracking temperature, humidity, and location in transit; emergency response logistics with 12-hour or less domestic U.S. deployment; inventory management systems for regulated sensitive products; fulfillment services dispatched from a dedicated service center with over 17 years of operation as of the filing date.
Revenue Model
Bundled service fees covering proprietary reusable packaging, Sentry temperature and humidity monitoring technology, emergency response logistics, and fulfillment services. The filing states that technical services and technological offerings are bundled with emergency response and perishable packaging and are not treated as separate revenue streams. A leasing model is used for packaging systems.
Customers & Markets
Life sciences organizations requiring cold chain integrity for personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, biopharmaceuticals, and infectious substances. Named customer relationships include Fortune 500 firms, the City of Chicago, NATO, the United Nations, and government agencies. Future target markets cited in the 10-K include compounding pharmacies, GLP-1 transport, and high-end food packaging.
Geographic Exposure
Domestic U.S. operations with emergency response deployment capability of 12 hours or less within the United States, per the 10-K filed March 31, 2026. International customer relationships noted with NATO and the United Nations, though geographic revenue breakdown is not disclosed in the excerpts.
Source: SEC 10-K, filed 2026-03-31
Financial Snapshot
Loading...
